Clinical Cancer Nanomedicine.

[1]  David A. Geller,et al.  Negligible absorption of radiofrequency radiation by colloidal gold nanoparticles. , 2011, Journal of colloid and interface science.

[2]  A. Brenner,et al.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.

[3]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[4]  G. Marx,et al.  International Journal of Molecular Sciences the Ribonuclease a Superfamily in Humans: Canonical Rnases as the Buttress of Innate Immunity , 2022 .

[5]  M. Ferrari,et al.  Post-nano strategies for drug delivery: Multistage porous silicon microvectors. , 2017, Journal of materials chemistry. B.

[6]  M. Ferrari,et al.  Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice , 2012, Advanced functional materials.

[7]  Yvette N. Lamb,et al.  Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma , 2017, Drugs.

[8]  Kazuo Maruyama,et al.  Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. , 2008, International journal of pharmaceutics.

[9]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Ferrari,et al.  What does physics have to do with cancer? , 2011, Nature Reviews Cancer.

[11]  E. Tasciotti,et al.  Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. , 2015, Colloids and surfaces. B, Biointerfaces.

[12]  Mauro Ferrari,et al.  Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.

[13]  R. Laborde,et al.  A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.

[14]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[15]  M. Ferrari,et al.  Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  L. Leelawatwattana,et al.  Evolutionary changes to transthyretin: structure–function relationships , 2009, The FEBS journal.

[17]  V. Préat,et al.  RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.

[18]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[19]  Glenn P. Goodrich,et al.  Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease , 2016, International journal of toxicology.

[20]  D. Dickson,et al.  Tangential Flow Filtration for Highly Efficient Concentration of Extracellular Vesicles from Large Volumes of Fluid , 2018, Cells.

[21]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[22]  Mauro Ferrari,et al.  nan'o·tech·nol'o·gy n. , 2006, Nature nanotechnology.

[23]  M. Vallet‐Regí,et al.  Hybrid Collagenase Nanocapsules for Enhanced Nanocarrier Penetration in Tumoral Tissues. , 2015, ACS applied materials & interfaces.

[24]  M. Lubberink,et al.  Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. , 2012, Cancer cell.

[25]  Heidi Ledford.  Bankruptcy filing worries developers of nanoparticle cancer drugs , 2016, Nature.

[26]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[27]  Mauro Ferrari,et al.  Taking the vehicle out of drug delivery. , 2017, Materials today.

[28]  Zhiping Zhang,et al.  Nanotechnology based therapeutic modality to boost anti‐tumor immunity and collapse tumor defense , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[29]  L. Mayer,et al.  Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. , 2010, International journal of pharmaceutics.

[30]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[31]  A. Khvorova.  Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. , 2017, The New England journal of medicine.

[32]  Ralph Weissleder,et al.  Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.

[33]  Mauro Ferrari,et al.  Contribution of Kupffer cells to liposome accumulation in the liver. , 2017, Colloids and surfaces. B, Biointerfaces.

[34]  H. Harashima,et al.  The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. , 2013, Biological & pharmaceutical bulletin.

[35]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[36]  A. Mazumder,et al.  A Phase II Trial of Chloroquine in Combination with Bortezomib and Cyclophosphamide in Patients with Relapsed and Refractory Multiple Myeloma , 2014 .

[37]  K. Hynynen,et al.  To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[38]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[39]  B. Erickson,et al.  Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. , 2014, European journal of cancer.

[40]  Jess G Snedeker,et al.  The role of collagen crosslinks in ageing and diabetes - the good, the bad, and the ugly. , 2014, Muscles, ligaments and tendons journal.

[41]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[42]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[43]  Mauro Ferrari,et al.  An injectable nanoparticle generator enhances delivery of cancer therapeutics , 2016, Nature Biotechnology.

[44]  Qingqing Yang,et al.  Multistage Nanovehicle Delivery System Based on Stepwise Size Reduction and Charge Reversal for Programmed Nuclear Targeting of Systemically Administered Anticancer Drugs , 2015 .

[45]  M. Link,et al.  Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Curzio Rüegg,et al.  Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? , 2008, Nature Clinical Practice Oncology.

[47]  Yun Yen,et al.  CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing , 2016, Proceedings of the National Academy of Sciences.

[48]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[50]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[51]  M. Ferrari,et al.  Transport Oncophysics in silico, in vitro, and in vivo , 2014, Physical biology.

[52]  T. Boulikas,et al.  Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. , 2005, Anticancer research.

[53]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[54]  M. Ferrari,et al.  A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery , 2017, Scientific Reports.

[55]  Jun Wang,et al.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. , 2016, ACS nano.

[56]  Austin D. Swafford,et al.  Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes , 2008, Proceedings of the National Academy of Sciences.

[57]  A. Sood,et al.  RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. , 2016, Cancer treatment reviews.

[58]  K. Peter,et al.  Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators , 2015, The Journal of experimental medicine.

[59]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[60]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[61]  Hao Cheng,et al.  Hyaluronidase Embedded in Nanocarrier PEG Shell for Enhanced Tumor Penetration and Highly Efficient Antitumor Efficacy. , 2016, Nano letters.

[62]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[63]  R. Korn,et al.  Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.

[64]  E. Antonarakis,et al.  Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. , 2011, European journal of cancer.

[65]  Sei-Young Lee,et al.  Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows , 2009, Nanotechnology.

[66]  Jörg Huwyler,et al.  Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[67]  F. Lund-Johansen,et al.  Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA , 2016, mAbs.

[68]  F. Alexis.  Nano-polypharmacy to treat tumors: coencapsulation of drug combinations using nanoparticle technology. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[70]  Kirsten Sandvig,et al.  Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies , 2011 .

[71]  M. Ferrari,et al.  Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. , 2015, Cell reports.

[72]  I. Pollack,et al.  A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study , 2016, Journal of Neuro-Oncology.

[73]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[74]  Martin A. Nowak,et al.  Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy , 2014, PLoS Comput. Biol..

[75]  Giuseppe Pascazio,et al.  The preferential targeting of the diseased microvasculature by disk-like particles. , 2012, Biomaterials.

[76]  P. Wust,et al.  Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme , 2010, Journal of Neuro-Oncology.

[77]  M. C. Popescu,et al.  Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen , 2004, Clinical Cancer Research.

[78]  I. Kwon,et al.  Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[79]  M Ferrari,et al.  The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.

[80]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[81]  D. Yardley.  nab-Paclitaxel mechanisms of action and delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[82]  M. Bally,et al.  Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. , 1990, Cancer letters.

[83]  J. Snedeker,et al.  The role of collagen crosslinks in ageing and diabetes - the good, the bad, and the ugly , 2019, Muscle Ligaments and Tendons Journal.

[84]  F. Liu,et al.  Targeted cancer therapy with novel high drug-loading nanocrystals. , 2010, Journal of pharmaceutical sciences.

[85]  K. Syrigos,et al.  Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model , 2000, British Journal of Cancer.

[86]  M Ferrari,et al.  Nanovector delivery of siRNA for cancer therapy , 2012, Cancer Gene Therapy.

[87]  Jonathan Rasmussen,et al.  Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. , 2017, Nano letters.

[88]  A. Hill,et al.  Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey , 2016, Journal of extracellular vesicles.

[89]  Christopher E. Hart,et al.  Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[91]  Zachary W. Ulissi,et al.  Molecular recognition using corona phase complexes made of synthetic polymers adsorbed on carbon nanotubes , 2013, 2014 40th Annual Northeast Bioengineering Conference (NEBEC).

[92]  Sandra N. Ekdawi,et al.  Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications. , 2015, International journal of pharmaceutics.

[93]  D. Coulter,et al.  Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. , 1992, Cancer research.

[94]  D. Siemann,et al.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. , 2011, Cancer treatment reviews.

[95]  E. Winer,et al.  Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  P. Decuzzi,et al.  Design Maps for the Hyperthermic Treatment of Tumors with Superparamagnetic Nanoparticles , 2013, PloS one.

[97]  S. Tsuji,et al.  Platelet Shape Changes and Adhesion Under High Shear Flow , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[98]  J Szebeni,et al.  Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[99]  Mauro Ferrari,et al.  Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. , 2014, Cancer letters.

[100]  K. Garber.  Alnylam terminates revusiran program, stock plunges , 2016, Nature Biotechnology.

[101]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[102]  Joseph M DeSimone,et al.  Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[103]  F. Greco,et al.  Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection. , 2017, Journal of pharmaceutical sciences.

[104]  J. Wolchok,et al.  corrigenda to Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [Ann Oncol 26 (2015) 2375-2391, doi: 10.1093/annonc/mdv383] , 2016 .

[105]  Wen Jiang,et al.  Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. , 2015, ACS nano.

[106]  A. Giatromanolaki,et al.  Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  J. Cortes,et al.  Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. , 2016 .

[108]  Mauro Ferrari,et al.  Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.

[109]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[110]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[111]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[112]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[113]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[114]  Gang Bao,et al.  CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. , 2017, Chemical reviews.

[115]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[117]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[118]  R. Jain,et al.  Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. , 1989, Cancer research.

[119]  Hamidreza Ghandehari,et al.  Nanoparticle Uptake: The Phagocyte Problem. , 2015, Nano today.

[120]  Betty Y. S. Kim,et al.  Lessons from immuno-oncology: a new era for cancer nanomedicine? , 2017, Nature Reviews Drug Discovery.

[121]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[122]  Jim E Riviere,et al.  An index for characterization of nanomaterials in biological systems. , 2010, Nature nanotechnology.

[123]  Jaroslav Turánek,et al.  Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[124]  N. Svrzikapa,et al.  Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  T. Ishida,et al.  Accelerated clearance of PEGylated liposomes in rats after repeated injections. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[126]  Triantafyllos Stylianopoulos,et al.  Combining two strategies to improve perfusion and drug delivery in solid tumors , 2013, Proceedings of the National Academy of Sciences.

[127]  Sunil Krishnan,et al.  Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo. , 2010, ACS nano.

[128]  Klaus Jung,et al.  Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model , 2005, The Prostate.

[129]  T. Papoian,et al.  Safety of antisense oligonucleotide and siRNA-based therapeutics. , 2017, Drug discovery today.

[130]  Kenneth J. Shea,et al.  Tuning the Protein Corona of Hydrogel Nanoparticles: The Synthesis of Abiotic Protein and Peptide Affinity Reagents. , 2016, Accounts of chemical research.

[131]  J. Wolfram,et al.  Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[132]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[133]  M. Johnston,et al.  Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. , 2006, Biochimica et biophysica acta.

[134]  J. Frampton.  Mifamurtide: a review of its use in the treatment of osteosarcoma. , 2010, Paediatric drugs.

[135]  M. Ferrari,et al.  Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. , 2013, Cancer letters.

[136]  W. Parak,et al.  In situ detection of the protein corona in complex environments , 2017, Nature Communications.

[137]  Pieter Vader,et al.  Extracellular vesicles as drug delivery systems: lessons from the liposome field. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[138]  T. Yasuda,et al.  Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method. , 1993, Clinical chemistry.

[139]  N. Sasahira,et al.  A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2 , 2013, Investigational New Drugs.

[140]  W. Saltzman,et al.  Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies , 2015, ACS biomaterials science & engineering.

[141]  S. Bhatia,et al.  Protease-triggered unveiling of bioactive nanoparticles. , 2008, Small.

[142]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[143]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[144]  P. Cullis,et al.  Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. , 1994, Biochimica et biophysica acta.

[145]  Darrell R Boverhof,et al.  Comparative assessment of nanomaterial definitions and safety evaluation considerations. , 2015, Regulatory toxicology and pharmacology : RTP.

[146]  Bengt-Harald Jonsson,et al.  Protein adsorption onto silica nanoparticles: conformational changes depend on the particles' curvature and the protein stability. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[147]  R. Gonzalez,et al.  High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. , 2014, Clinical lymphoma, myeloma & leukemia.

[148]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[149]  Yoon Yeo,et al.  Recent advances in stealth coating of nanoparticle drug delivery systems. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[150]  Samir Mitragotri,et al.  Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium , 2013, Proceedings of the National Academy of Sciences.

[151]  R. Jain,et al.  Strategies for advancing cancer nanomedicine. , 2013, Nature materials.

[152]  W. Baumgartner,et al.  Red blood cell orientation in pulmonary capillaries and its effect on gas diffusion. , 2003, Journal of applied physiology.

[153]  M. Ferrari,et al.  Mild Hyperthermia Enhances Transport of Liposomal Gemcitabine and Improves In Vivo Therapeutic Response , 2015, Advanced healthcare materials.

[154]  Iseult Lynch,et al.  Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[155]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[156]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[157]  Jun Wang,et al.  Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy , 2016, Proceedings of the National Academy of Sciences.

[158]  Mauro Ferrari,et al.  Multistage vector (MSV) therapeutics. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[159]  D. Lane,et al.  Designer combination therapy for cancer , 2006, Nature Biotechnology.

[160]  C. Presant,et al.  Successful imaging of human cancer with indium‐111‐labeled phospholipid vesicles , 1988, Cancer.

[161]  M. Ferrari,et al.  Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. , 2014, Biomaterials.

[162]  Christian Celia,et al.  Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors , 2013, Expert opinion on drug delivery.

[163]  Dai Fukumura,et al.  Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.

[164]  J. Wolfram,et al.  Extracellular vesicle therapeutics for liver disease , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[165]  Francesco M Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[166]  A. Gabizon,et al.  Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. , 2008, Clinical lymphoma & myeloma.

[167]  M. Ferrari,et al.  High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. , 2013, ACS nano.

[168]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[169]  Steven A. Curley,et al.  Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles , 2010, Clinical Cancer Research.

[170]  G. Gerken,et al.  Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. , 2014, International immunology.

[171]  Glen J Weiss,et al.  Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[172]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  Farnaz Niroui,et al.  In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. , 2012, ACS nano.

[174]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[175]  M. Ferrari,et al.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. , 2017, Seminars in immunology.

[176]  D. Tzemach,et al.  Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.

[177]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[178]  Daniel T. Fisher,et al.  Intraoperative intravital microscopy permits the study of human tumour vessels , 2016, Nature Communications.

[179]  M. Ferrari,et al.  A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells. , 2016, Pharmacological research.

[180]  C. Presant,et al.  Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes , 1990, The Lancet.

[181]  J. Whitfield,et al.  Strategies to Inhibit Myc and Their Clinical Applicability , 2017, Front. Cell Dev. Biol..

[182]  M. Ferrari,et al.  Porous silicon microparticles for delivery of siRNA therapeutics. , 2015, Journal of visualized experiments : JoVE.

[183]  M. Ferrari,et al.  A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis , 2016, Advanced healthcare materials.

[184]  R. Langer,et al.  Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. , 2006, Journal of pharmaceutical sciences.

[185]  Manish R. Sharma,et al.  Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. , 2015 .

[186]  G. Batist,et al.  Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy , 2002, Expert opinion on pharmacotherapy.

[187]  A. Schneeweiss,et al.  Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[188]  R. Zhou,et al.  RES blockade: A strategy for boosting efficiency of nanoparticle drug , 2015 .

[189]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[190]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[191]  Karen Campbell,et al.  64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[192]  R. Osieka,et al.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[193]  M. Carafa,et al.  Liposomal chemotherapeutics. , 2013, Future oncology.

[194]  V. Trezza,et al.  Human serum albumin: from bench to bedside. , 2012, Molecular aspects of medicine.

[195]  Alicia J. Zollinger,et al.  Fibronectin, the extracellular glue. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[196]  B. Fadeel,et al.  In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy. , 2011, Biochemical pharmacology.

[197]  T. Stinchcombe,et al.  Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. , 2007, Nanomedicine.

[198]  K. Giese,et al.  First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  Imre Mäger,et al.  Extracellular vesicles: biology and emerging therapeutic opportunities , 2013, Nature Reviews Drug Discovery.

[200]  V. Torchilin,et al.  Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety , 2013, Proceedings of the National Academy of Sciences.

[201]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.